Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib Combination versus Sunitinib in Patients with Advanced RCC By Ogkologos - February 11, 2025 889 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a final analysis of the JAVELIN Renal 101 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR EMA Recommends Extension of Indications for Niraparib September 29, 2020 FDA Grants Accelerated Approval to Pembrolizumab for HER2-positive Gastric Cancer May 10, 2021 Can Eating Grilled or Charred Foods Cause Cancer? January 10, 2023 Finding Purpose in Sharing Your Story: A Q&A With Esophageal Cancer... January 5, 2023 Load more HOT NEWS Navigating the Challenges of Gynecologic Cancer Survivorship: An Expert Perspective EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for Non-Small Cell Lung... Reunión anual de la American Society of Clinical Oncology de 2021:...
